ArticleJournal of the National Cancer Center2025
Global burden of cervical cancer: current estimates, temporal trend and future projections based on the GLOBOCAN 2022.
Article in Journal of the National Cancer Center, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 141 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
141 citing papers in PubMed, 4 syntheses or guidelines pooled it.
- Determinants of human papillomavirus vaccination uptake in Nigeria: a mixed-methods systematic review.BMC public health · 2026Pooled it
- Diagnostic and clinical utility of ultrasound elastography for uterine cervical neoplasms-a comprehensive systematic review and meta-analysis.Abdominal radiology (New York) · 2026Pooled it
- Efficacy of focused ultrasound for HPV clearance and cervical LSIL treatment: a meta-analysis.Scientific reports · 2026Pooled it
- Immunoconjugates in cervical cancer: a bibliometric and thematic mapping analysis of global research trends, 2015-2024.Frontiers in oncology · 2026Pooled it
- Trial
- Efficacy and durability of immediate versus delayed single-dose HPV vaccination for persistent infection among young women in Kenya: a randomized, blinded, cross-over clinical trial.Nature communications · 2026Trial
- Comparative validation of a cost-effective in-house 3D-printed LLETZ simulator versus a commercial training model.Archives of gynecology and obstetrics · 2026Trial
- Acupuncture combined with immunotherapy for recurrent and metastatic cervical cancer: a pilot RCT protocol.Frontiers in oncology · 2026Trial
- Cervical cancer and screening: Knowledge, attitudes, and adherence among university students in Italy.Human vaccines & immunotherapeutics · 2026Article
- Resource-Adapted Triage Strategies for Women Testing HPV Positive With Self-Collected Vaginal Samples in Cameroon.International journal of cancer · 2026Article
- Financing of Human Papillomavirus Vaccination in Africa: A Scoping Review.Health science reports · 2026Review
- Endolysosomal routing combined with immune stimulation enhances anti-tumor efficacy of an HPV16 mRNA therapeutic vaccine.Materials today. Bio · 2026Article
- Therapy resistance-related ncRNAs in cervical cancer: biomarkers and therapeutic targets.Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences · 2026Review
- Colposcopic Imaging Carries Most of the Signal: Externally Validated Tri-Modal Integration of Imaging, Vaginal Microbiome, and Coagulation-Immune Data in HPV-Associated Co-Infection.Diagnostics (Basel, Switzerland) · 2026Article
- Successful treatment of massive stage IIIB cervical cancer with a spindle cell component: A case report.Medicine · 2026Article
- Clinicopathological and Prognostic Significance of TROP2 and HER3 Expression in Early-Stage Cervical Carcinoma.Diagnostics (Basel, Switzerland) · 2026Article
- Impact of Post-Primary Treatment Hormone Replacement Therapy on Survival in Women with Cervical Cancer.Cancers · 2026Article
- Wastewater-Based Surveillance of Human Papillomavirus Genotype Diversity.JAMA network open · 2026Article
- Methylene blue-modified hexagonal boron nitride nanostructured immunosensor for early detection of HPV16 E6 oncoprotein.Mikrochimica acta · 2026Article
- Glycolytic reprogramming and the EMT drive cervical cancer progression via the NQO1/HIF1α-SIX1 axis.iScience · 2026Article
81 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Cervical cancer is the only cancer that can be eliminated worldwide. Tracking the latest burden of cervical cancer is critical toward the targets set by World Health Organization (WHO) to eliminate cervical cancer as a major public health problem. Methods: All data were extracted from the Global Cancer Observatory (GLOBOCAN) 2022. Age-standardized incidence rate (ASIR) and mortality rates (ASMR) of cervical cancer were compared and linked to Human Development Index (HDI) between populations. The estimated annual percentage changes (EAPCs) were used to characterize the temporal trend in ASIR/ASMR, and demographic estimates were projected up to 2050. Results: Globally, an estimated 662,044 cases (ASIR: 14.12/100,000) and 348,709 deaths (ASMR: 7.08/100,000) from cervical cancer occurred in 2022, corresponding to the fourth cause of cancer morbidity and mortality in women worldwide. Specifically, 42 % of cases and 39 % of deaths occurred in China (23 % and 16 %) and India (19 % and 23 %). Both ASIR and ASMR of cervical cancer decreased with HDI, and similar decreasing links were observed for both early-onset (0-39 years) and late-onset (≥40 years) cervical cancer. Both ASIR and ASMR of overall cervical cancer showed decreasing trends during 2003-2012 (EAPC: 0.04 % and -1.03 %); however, upward trends were observed for early-onset cervical cancer (EAPC: 1.16 % and 0.57 %). If national rates in 2022 remain stable, the estimated cases and deaths from cervical cancer are projected to increase by 56.8 % and 80.7 % up to 2050. Moreover, the projected increase of early-onset cervical cancer is mainly observed in transitioning countries, while decreased burden is expected in transitioned countries. Conclusions: Cervical cancer remains a common cause of cancer death in many countries, especially in transitioning countries. Unless scaling-up preventive interventions, human papillomavirus (HPV) vaccination and cervical cancer screening, as well as systematic cooperation within government, civil societies, and private enterprises, the global burden of cervical cancer would be expected to increase in the future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.